Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Keep Transport Services Public Warn Unions, UK
UNISON and UNITE are calling on North Somerset Council to put a stop to plans to privatise transport services, warning that outsourcing could put vulnerable young children at risk.

Instrumental Variable Analysis: Is The Cure Worse Than The Disease?
Causal inference is challenging in all non-experimental studies because of the possibility of hidden bias. Hidden bias may exist as a result of failure to control for unobservable factors, such as doctors" practice/prescription patterns.
News of the day
National Association Of Pediatric Nurse Practitioners Supports The Preserving Patient Access To Primary Care Act
The National Association of Pediatric Nurse Practitioners (NAPNAP) praises Representative Allyson Schwartz and nearly 100 cosponsors of The Preserving Patient Access to Primary Care Act for their leadership in health care reform. This legislation, which will increase the number of primary care providers and improve patient access to primary care services, is a critical step if we truly are to reform our health care delivery system. Our nation needs leaders like Representative Schwartz to affect real and lasting change in our health care system.
Diagnostics

Small Clinical Trial Examines Drug's Ability To Reduce HIV In Body

In the first human trial of GlaxoSmithKline"s (GSK) experimental HIV drug S/GSK1349572, the drug was able to reduce HIV to undetectable levels in 70 percent of the 35 patients taking the treatment for 10 days, according to findings presented at the International AIDS Society"s conference in Cape Town, South Africa, Bloomberg reports. The drug decreased the virus in the body "without the signs of resistance linked to treatments from" Merck"s Isentress and Gilead Sciences" Elvitegravir, according to Bloomberg. GSK will begin a larger trial of the drug this month, Sherene Min, the director of clinical pharmacology discovery medicine for GSK, said. Michael Saag, director of the Center for AIDS Research at the University of Alabama, who is not affiliated with the study, said the scale of viral reduction was "spectacular," adding, "In 10 days to go to undetectable is pretty strong. This thing"s working" (Bennett, 7/21). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009